Tesamorelin binds to and stimulates GHRH receptors with similar potency to endogenous GHRH. Aside from GH release, it can have nootropic benefits and neuroprotective benefits, it can reduce triglycerides, decrease carotid intima-media thickness (cIMT), reduce visceral fat, and reduce CRP. Tesamorelin as a drug is FDA Approved (Egrifta) for reduction of visceral adipose tissue in HIV patients with lypodystrophy, demonstrating the immense data in support of this product and the efficacy seen even in severely immune-compromised people.